Archive · 9 Aug 2025
Biocon Biologics Reports Strong Q1 Growth, Oncology Drives Revenue
Biocon Biologics, a part of Biocon, did very well in the last three months.
Their sales went up by 18%, and their profits increased even more.
They're selling more medicines in North America and Europe, particularly those that treat cancer.
The company also got approval to sell a new type of insulin in the US.
To help them grow, Biocon raised a lot of money by selling new shares.
They plan to use this money to pay off some debts and to own more of Biocon Biologics.
The company is hoping to become a global leader in its field.
Biocon Biologics' revenue grew 18% year-on-year to ₹2,458 crore in Q1.
Ebitda rose 36% on a like-for-like basis to ₹645 crore, with a margin of 26%.
North America and Europe drove growth, especially in oncology.
The company received FDA approval for Kirsty (Insulin Aspart).
Biocon concluded a ₹4,500 crore equity fundraise in June 2025.
- Who
- Biocon Biologics
- What
- Biocon Biologics reported strong Q1 revenue and profit growth.
- When
- Q1 FY26, ended June 2025
- Where
- North America, Europe
- Why
- Driven by strong performance in key markets and new product approvals.
- Revenue Growth (YoY)
- 18%
- Ebitda Growth (Like-for-like)
- 36%
- Ebitda Margin
- 26%
- Q1 Revenue
- ₹2,458 crore
- Q1 Ebitda
- ₹645 crore
- Fundraise Amount
- ₹4,500 crore
